Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Court approves detention of man who held intern at knifepoint at airport
09/13/2026 10:13 PM - Business
Mandarin Airlines A321neo makes domestic debut on domestic route
09/13/2026 07:31 PM - Sports
Dwight Howard headlines New Taipei Kings charity event
09/13/2026 06:07 PM - Society
Western Taiwan sees hot weather Sunday
09/13/2026 05:38 PM - Culture
French film critic helped bring Taiwan New Cinema to world: Minister
09/13/2026 05:17 PM